Sickle cell disease (SCD), a genetic blood disorder affecting nearly eight million people worldwide, has long been associated with painful and unpredictable vaso-occlusive crises (VOCs). These episodes often lead to emergency hospital admissions, long stays, and permanent organ damage. However, a groundbreaking solution developed by Sanius Health, a London-based digital health company, could soon offer patients the ability to predict and manage these crises before they occur.
Sanius Health has developed an artificial intelligence (AI) platform that uses predictive analytics to forecast VOCs with up to 92% sensitivity. By combining real-time biometric data from wearables, patient-reported outcomes, and clinical records, the AI system generates daily risk scores, alerting patients and healthcare providers when thresholds for a potential crisis are met. This early warning system allows for proactive intervention, reducing the need for emergency room visits and hospitalizations.
The impact of this technology on patient care is transformative. It empowers patients with greater control over their condition and alleviates the anxiety of not knowing when a crisis might strike. It also gives clinicians critical time to act and adjust treatment plans, improving outcomes and quality of life.
Sanius Health’s technology has been validated through real-world studies, with results showing fewer emergency admissions and shorter hospital stays for patients using the system. By harnessing the power of AI and wearable technology, Sanius Health is paving the way for a future where rare blood disorders like sickle cell disease can be managed with foresight and precision. This innovation not only promises better care for individuals but also holds the potential to revolutionize how healthcare systems approach rare diseases globally.
Artículo escrito por el equipo de redacción de Health Tech world
01/10/2025
Source:
Health Tech world